/SIBN
SIBN Stock - SI-BONE, Inc.
Healthcare|Medical - DevicesNASDAQ
$20.38+0.64%
+$0.13 (+0.64%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).86
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+17.8%upside
Target: $24.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SIBN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$20.18 – $20.58
TARGET (TP)$24.00
STOP LOSS$18.75
RISK/REWARD1:2.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.76
52W High$20.80
52W Low$12.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $167.18M | $138.89M | $106.41M | $90.15M | $73.39M |
| Gross Profit | $132.12M | $109.42M | $90.70M | $79.72M | $64.48M |
| Gross Margin | 79.0% | 78.8% | 85.2% | 88.4% | 87.9% |
| Operating Income | $-35,248,000 | $-46,931,000 | $-59,609,000 | $-51,670,000 | $-38,567,000 |
| Net Income | $-30,913,000 | $-43,336,000 | $-61,256,000 | $-56,572,000 | $-43,697,000 |
| Net Margin | -18.5% | -31.2% | -57.6% | -62.8% | -59.5% |
| EPS | $-0.75 | $-1.13 | $-1.79 | $-1.71 | $-1.50 |
Company Overview
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$21
Average Target
↑ 4.7% Upside
Now
$19
Low
$21
Average
$25
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 6th 2024 | Needham | Reiterated | Buy | $19← $27 |
| March 28th 2024 | Piper Sandler | Initiation | Overweight | $25 |
| October 12th 2022 | Jefferies | Initiation | Buy | $20 |
Earnings History & Surprises
SIBNBeat Rate
81%
Last 16 quarters
Avg Surprise
+14.6%
EPS vs Estimate
Beats / Misses
13/3
Last 12 quarters
Latest EPS
$-0.11
Q4 2025
EPS Surprise History
Q1 24
+6.9%
$-0.27vs$-0.29
Q2 24
+6.9%
$-0.27vs$-0.29
Q3 24
+15.4%
$-0.22vs$-0.26
Q4 24
+27.3%
$-0.16vs$-0.22
Q1 25
+24.4%
$-0.11vs$-0.15
Q2 25
+37.5%
$-0.15vs$-0.24
Q3 25
+26.3%
$-0.14vs$-0.19
Q4 25
+31.3%
$-0.11vs$-0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2026 | Nov 9, 2026 | — | — | — | — |
Q3 2026 | Aug 3, 2026 | — | — | — | — |
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $-0.13 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.16 | $-0.11 | +31.3% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $-0.19 | $-0.14 | +26.3% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $-0.24 | $-0.15 | +37.5% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $-0.15 | $-0.11 | +24.4% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.22 | $-0.16 | +27.3% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.26 | $-0.22 | +15.4% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.29 | $-0.27 | +6.9% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $-0.29 | $-0.27 | +6.9% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.33 | $-0.25 | +24.2% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.41 | $-0.30 | +26.8% | ✓ BEAT |
Q2 2023 | May 1, 2023 | $-0.41 | $-0.32 | +22.0% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.42 | $-0.32 | +23.8% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.45 | $-0.41 | +8.9% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.49 | $-0.54 | -10.2% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.43 | $-0.52 | -20.9% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.37 | $-0.43 | -16.2% | ✗ MISS |
Latest News
Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $23
📈 PositiveBenzinga•Dec 18, 2025, 03:58 PM
Canaccord Genuity Maintains Buy on SI-BONE, Raises Price Target to $27
📈 PositiveBenzinga•Dec 17, 2025, 08:24 PM•Also:
Needham Maintains Buy on SI-BONE, Raises Price Target to $27
📈 PositiveBenzinga•Dec 16, 2025, 12:11 PM
Morgan Stanley Maintains Overweight on SI-BONE, Raises Price Target to $23
📈 PositiveBenzinga•Dec 2, 2025, 05:54 PM
SI-BONE shares are trading higher after the company reported Q3 earnings and revenue above estimates and raised its FY2025 sales guidance.
📈 PositiveBenzinga•Nov 11, 2025, 02:44 PM
SI-BONE Raises FY2025 Sales Guidance from $195.000M-$198.000M to $198.000M-$200.000M vs $196.584M Est
📈 PositiveBenzinga•Nov 10, 2025, 09:10 PM
SI-BONE Q3 EPS $(0.11) Beats $(0.17) Estimate, Sales $48.656M Beat $46.667M Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:09 PM
Truist Securities Maintains Buy on SI-BONE, Lowers Price Target to $20
➖ NeutralBenzinga•Oct 15, 2025, 03:38 PM
Frequently Asked Questions about SIBN
What is SIBN's current stock price?
SI-BONE, Inc. (SIBN) is currently trading at $20.38 per share. The stock has moved +0.64% today.
What is the analyst price target for SIBN?
The average analyst price target for SIBN is $24.00, based on 1 analyst.
What sector is SI-BONE, Inc. in?
SI-BONE, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is SIBN's market cap?
SI-BONE, Inc. has a market capitalization of $0.88 billion, making it a small-cap company.
Does SIBN pay dividends?
No, SI-BONE, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAIRS
AirSculpt Technologies, Inc.
$2.19
Mkt Cap: $0.1B
AQST
Aquestive Therapeutics, Inc.
$5.80
Mkt Cap: $0.6B
AVNS
Avanos Medical, Inc.
$11.67
Mkt Cap: $0.5B
AVXL
Anavex Life Sciences Corp.
$3.67
Mkt Cap: $0.3B
BFLY
Butterfly Network, Inc.
$3.56
Mkt Cap: $0.9B
CLPT
ClearPoint Neuro, Inc.
$14.20
Mkt Cap: $0.4B
INNV
InnovAge Holding Corp.
$6.00
Mkt Cap: $0.8B
OFIX
Orthofix Medical Inc.
$15.46
Mkt Cap: $0.6B
PACB
Pacific Biosciences of California, Inc.
$1.84
Mkt Cap: $0.6B
VREX
Varex Imaging Corporation
$12.29
Mkt Cap: $0.5B
Explore stocks similar to SIBN for comparison